{"nctId":"NCT04102007","briefTitle":"A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","startDateStruct":{"date":"2019-11-12","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":244,"armGroups":[{"label":"Risankizumab","type":"OTHER","interventionNames":["Drug: Risankizumab"]}],"interventions":[{"name":"Risankizumab","otherNames":["SKYRIZI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 months before Baseline (Week 0).\n* Participant must have been on labeled secukinumab or ixekizumab treatment for at least 6 months and are experiencing suboptimal response at time of Screening and Baseline visits.\n* Participant must have a Body Surface Area (BSA) 3%- \\<10% and Static Physician Global Assessment (sPGA) 2/3\n* Participant must be eligible for continued biologic therapy as assessed by the investigator.\n\nExclusion Criteria:\n\n* History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis, psoriatic arthritis.\n* Participant with active skin disease other than plaque psoriasis that could interfere with the assessment of plaque psoriasis.\n* History of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.\n* History of major surgery within 12 weeks prior to Baseline or planned to be performed during the conduct of the trial as assessed by the investigator.\n* Participant with exposure to risankizumab or any IL-23 inhibitors.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1","description":"The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0","description":"The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are:\n\npain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a sPGA Clear Response (sPGA 0)","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1","description":"The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a PSS 0","description":"The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are:\n\npain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve sPGA 0/1","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve sPGA 0","description":"The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":244},"commonTop":["COVID-19","NASOPHARYNGITIS"]}}}